Scinai Immunotherapeutics Ltd ADR (SCNI)

$2.55 -0.70 (-21.54%)
Market Cap 3.25M
Revenue (ttm) 660,000.00
Net Income (ttm) 4.80M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 727.27%
Debt to Equity Ratio 0.03
Volume 642,600
Avg Vol 439,270
Day's Range N/A - N/A
Shares Out 1.00M
Stochastic %K 8%
Beta 2.10
Analysts Strong Buy
Price Target $8.00

Latest News on SCNI

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Jun 5, 2025, 9:00 AM EDT - 2 days ago

Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

May 30, 2025, 7:00 AM EDT - 8 days ago

Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn

Scinai Announces Annual Financial Results for 2024

May 7, 2025, 4:01 PM EDT - 4 weeks ago

Scinai Announces Annual Financial Results for 2024

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

May 1, 2025, 7:00 AM EDT - 5 weeks ago

Scinai Immunotherapeutics and Pincell to Host Webinar on a Blockbuster Drug Candidate for Devastating Rare Skin Diseases

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Mar 27, 2025, 9:25 AM EDT - 2 months ago

Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

Mar 17, 2025, 7:00 AM EDT - 2 months ago

Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Mar 5, 2025, 7:30 AM EST - 3 months ago

SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Jan 6, 2025, 7:31 AM EST - 5 months ago

Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Dec 16, 2024, 9:25 AM EST - 6 months ago

Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dec 5, 2024, 8:25 AM EST - 6 months ago

Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Nov 27, 2024, 8:00 AM EST - 6 months ago

Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Nov 22, 2024, 7:15 AM EST - 7 months ago

Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Oct 31, 2024, 6:59 AM EDT - 7 months ago

Scinai Leadership to Showcase Company's cGMP Biologics CDMO and Innovative I&I pipeline during BIO-Europe 2024

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

Sep 16, 2024, 7:00 AM EDT - 9 months ago

Scinai to Host Online Expert Panel on Plaque Psoriasis Treatment and Intralesional Injections of anti-IL-17A/F VHH Antibodies

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Sep 9, 2024, 11:12 AM EDT - 9 months ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Amir Reichman, CEO of Scinai Immunotherapeutics Ltd.

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Aug 29, 2024, 6:31 AM EDT - 10 months ago

Scinai Regains Full Compliance with Nasdaq Listing Requirements

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Aug 21, 2024, 8:45 AM EDT - 10 months ago

Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Aug 20, 2024, 2:28 PM EDT - 10 months ago

Scinai Immunotherapeutics Ltd. (SCNI) Q2 2024 Earnings Call Transcript

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Aug 20, 2024, 9:30 AM EDT - 10 months ago

Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Aug 15, 2024, 7:00 AM EDT - 10 months ago

Scinai Publishes Q2 2024 Financial Results and Provides Business Update; Restructures $29 Million Bank Loan to Equity; On Track to Regain Nasdaq Compliance by August 23

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Aug 13, 2024, 7:00 AM EDT - 10 months ago

Scinai Announces Signing of Loan Restructuring Agreement with European Investment Bank; Converting Approximately $29 million of Debt to Preferred Equity Convertible into 19.5% Common Equity

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Jul 23, 2024, 7:00 AM EDT - 11 months ago

Scinai Immunotherapeutics Announces Positive Regulatory Feedback from the PEI on the path for Phase 1/2a in Plaque Psoriasis with its anti-IL-17 nanoAb

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Jul 15, 2024, 12:31 PM EDT - 11 months ago

Scinai Immunotherapeutics stock surges 55% on breakthrough psoriasis treatment results

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Jul 15, 2024, 7:00 AM EDT - 11 months ago

Scinai Immunotherapeutics Announces promising results in an in-vivo proof-of-concept psoriatic human skin model

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Jul 8, 2024, 8:14 AM EDT - 11 months ago

Scinai Immunotherapeutics Announces Receipt of an Updated Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Jul 3, 2024, 9:32 AM EDT - 1 year ago

Scinai Immunotherapeutics Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Jul 2, 2024, 8:12 AM EDT - 1 year ago

Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Jun 13, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Jun 7, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity Requirement

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

May 24, 2024, 4:01 PM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining Compliance

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

May 15, 2024, 4:01 PM EDT - 1 year ago

Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business Update

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

May 6, 2024, 9:21 AM EDT - 1 year ago

Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and Appeal

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Apr 10, 2024, 7:00 AM EDT - 1 year ago

Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMG

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing Services

Scinai leadership to attend BIO-Europe Spring 2024

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Scinai leadership to attend BIO-Europe Spring 2024

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Feb 29, 2024, 8:45 AM EST - 1 year ago

Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Feb 13, 2024, 7:00 AM EST - 1 year ago

Scinai Welcomes Liat Halpert as Head of Business Development and Sales

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Jan 25, 2024, 10:26 AM EST - 1 year ago

Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet Prize

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Jan 4, 2024, 4:01 PM EST - 1 year ago

Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Jan 4, 2024, 6:15 AM EST - 1 year ago

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Dec 29, 2023, 9:21 AM EST - 1 year ago

Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Dec 27, 2023, 7:15 AM EST - 1 year ago

Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Dec 12, 2023, 7:26 AM EST - 1 year ago

Scinai Announces Promising Results in a Psoriatic Human Skin Model

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

Dec 11, 2023, 8:11 AM EST - 1 year ago

Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drug

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

Nov 29, 2023, 9:25 AM EST - 1 year ago

European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Nov 20, 2023, 7:30 AM EST - 1 year ago

Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity Rule

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

Nov 6, 2023, 7:30 AM EST - 1 year ago

Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business Unit

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

Nov 3, 2023, 4:30 PM EDT - 1 year ago

Scinai Immunotherapeutics Provides Update Regarding Nasdaq Compliance

European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot

Oct 31, 2023, 9:00 AM EDT - 1 year ago

European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai's recent strategic pivot

Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 31, 2023, 8:23 AM EDT - 1 year ago

Scinai Reports Third Quarter 2023 Financial Results and Provides Business Update